INVENTIONS FOR LICENSE
MCL 2725.0: Treatment of Sequelae of Psychiatric Disorders
David Borsook, M.D., Ph.D., et al.
- Conditions associated with psychiatric disorders
- Obesity caused by schizophrenia
- Pain insensitivity caused by schizophrenia
Background and DescriptionMany psychiatric disorders such as schizophrenia, in addition to being primarily characterized by abnormal mental/thought processes, are associated with an increased incidence of obesity. Recent studies reveal that this may be due to the illness' neuropathology rather than simply the patients' inability to afford healthier foods. Schizophrenics appear to be particularly susceptible to the detrimental medical sequelae of obesity, including a host of cardiovascular risk factors. The present invention capitalizes on recent discoveries concerning the reward and satiety pathways of psychiatric patients, and features novel combinations of specific antipsychotic medications with compounds of another drug type. Such combinations may be useful in managing several physically degrading pathological conditions resulting from psychiatric disorders.
Potential Commercial UsesThis invention comprises methods to treat weight gain and obesity associated with psychiatric disorders. These novel combinations of drugs offer potentially advantageous ways to treat and manage these serious conditions that arise as a consequence of psychiatric disorders like schizophrenia, which are currently not amenable to conventional drug treatment.
Publication and Patent Status
McLean Hospital is the owner of a pending U.S. patent application claiming this invention.
McLean Hospital is offering a worldwide exclusive license to this technology.
For more information, please contact:David J. Glass, Ph.D.
Senior Associate Director, Technology Transfer
McLean Hospital Research Administration
115 Mill Street
Belmont, MA 02478-9106
(617) 855-3825 - tel
(617) 855-3745 - fax